Repligen
RGEN
#2397
Rank
NZ$13.54 B
Marketcap
NZ$239.93
Share price
-1.80%
Change (1 day)
19.41%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of March 2026 : NZ$1.16 Billion

According to Repligen 's latest financial reports the company's total debt is NZ$1.16 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31NZ$1.19 B-2.1%
2024-12-31NZ$1.21 B8.11%
2023-12-31NZ$1.12 B68.96%
2022-12-31NZ$0.66 B24.31%
2021-12-31NZ$0.53 B40.4%
2020-12-31NZ$0.38 B-2.37%
2019-12-31NZ$0.39 B153.42%
2018-12-31NZ$0.15 B10.4%
2017-12-31NZ$0.13 B1.61%
2016-12-31NZ$0.13 B
2005-03-31NZ$0.16 M31.36%
2004-03-31NZ$0.12 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
NZ$108.43 B 9,168.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
NZ$73.43 B 6,176.87%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
NZ$32.59 B 2,685.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$78.99 B 6,651.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
NZ$32.89 M-97.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
NZ$0.50 B-57.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
NZ$0.69 B-40.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
NZ$0.49 B-57.78%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
NZ$2.44 B 109.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
NZ$5.20 B 344.47%๐Ÿ‡บ๐Ÿ‡ธ USA